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S U M M A R Y
Background: Severe community-acquired pneumonia (SCAP) is a fatal disease. This study was conducted
to describe an outcome analysis of the intensive care units (ICUs) of Turkey.
Methods: This study evaluated SCAP cases hospitalized in the ICUs of 19 different hospitals between
October 2008 and January 2011. The cases of 413 patients admitted to the ICUs were retrospectively
analyzed.
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H. Erdem et al. / International Journal of Infectious Diseases 17 (2013) e768–e772 ee769Results: Overall 413 patients were included in the study and 129 (31.2%) died. It was found that bilateral
pulmonary involvement (odds ratio (OR) 2.5, 95% conﬁdence interval (CI) 1.1–5.7) and CAP PIRO score
(OR 2, 95% CI 1.3–2.9) were independent risk factors for a higher in-ICU mortality, while arterial
hypertension (OR 0.3, 95% CI 0.1–0.9) and the application of non-invasive ventilation (OR 0.2, 95% CI
0.1–0.5) decreased mortality. No culture of any kind was obtained for 90 (22%) patients during the
entire course of the hospitalization. Blood, bronchoalveolar lavage, and non-bronchoscopic lavage
cultures yielded enteric Gram-negatives (n = 12), followed by Staphylococcus aureus (n = 10),
pneumococci (n = 6), and Pseudomonas aeruginosa (n = 6). For 22% of the patients, none of the culture
methods were applied.
Conclusions: SCAP requiring ICU admission is associated with considerable mortality for ICU patients.
Increased awareness appears essential for the microbiological diagnosis of this disease.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Community-acquired pneumonia (CAP) is a common and
serious infection worldwide. Severe CAP (SCAP) is usually deﬁned
as pneumonia that requires intensive care unit (ICU) admission.
Although 2–20% of CAP patients require ICU admission,1,2 the
mortality rates can be as high as 20–50%.3,4 These patients
commonly have comorbidities and impaired host defenses, and
invasive procedures are frequently applied.5 Studies have shown
that clinicians frequently either overestimate6 or underestimate7
the severity of CAP. Once known as the ‘captain of the men of
death’, pneumonia is known to be one of the most fatal forms of
acute infectious diseases.8 However, mortality indicators of CAP in
the ICU have not yet been detailed in Turkey, which is located at
the intersection of Asia and Europe. Thus, the primary endpoint of
this study was to perform an outcome analysis of CAP patients in
the ICUs in this part of the world.
2. Methods
This multicenter, retrospective, cross-sectional, observational
cohort study was carried out in the ICUs of different hospitals in
Turkey. A total of 19 ICUs from 12 different provinces of Turkey
participated in the study. Consecutive patients aged 16 years
with conclusive evidence of CAP as the primary diagnosis,
conﬁrmed by chest radiography, during the period October 2008
to January 2011, were enrolled. Patients were admitted to the ICU
either for mechanical ventilation or because they were judged to
be in an unstable condition requiring intensive care. Pneumonia
was deﬁned as a new inﬁltrate on the chest roentgenogram and
two out of six clinical signs of pneumonia: cough, production of
sputum, signs of consolidation on respiratory auscultation,
temperature >38 8C or <35 8C, leukocytosis (white blood cell
count (WBC) >10  109/l) or leukopenia (WBC <4  109/l), and
more than 10% rods.9 CAP was considered as severe (SCAP) when it
required ICU admission. Shock was deﬁned as a systolic blood
pressure of <90 mmHg unresponsive to ﬂuid administration, or
the need for vasopressors for >4 h. Patients with pulmonary
tuberculosis and those residing in nursing homes were excluded.
Empirical antibiotic treatment was started following the clinical
diagnosis and just after obtaining samples for culture. The patients
were followed daily until death or complete cure. This study was
approved by the local ethics committee.
2.1. Data collection
The following demographic, clinical, and laboratory data were
collected for each patient with SCAP from the participating centers
using a computer database: age, gender, smoking and alcoholhabits, co-morbid illnesses, use of antimicrobials according to Turkish
guidelines,10 immunosuppressive drugs or systemic and inhaler
corticosteroids used in the last 3 months, clinical and laboratory
parameters, chest radiography ﬁndings, pneumonia severity index
(PSI), CAP predisposition, insult, response, and organ dysfunction
(PIRO) and CURB-65 scores, presence of septic shock, various
supportive care applications, and length of hospital and ICU stays.
2.2. Microbiological investigations
Blood cultures and bronchoalveolar lavage (BAL) or non-
bronchoscopic lavage (NBL) or deep tracheal aspirate (DTA) or
sputum cultures obtained within 48 h of ICU admission from the
emergency department were included. The culture results of patients
transferred to the ICU from wards where they had been hospitalized
for more than 48 h were excluded to prevent the inclusion of
nosocomial isolates. Since there was ongoing debate regarding the
quality of sputum cultures in various scientiﬁc platforms, and
because a number of centers did not quantify DTA specimens in our
study, these results were excluded. The threshold of quantitative
cultures for BAL and NBL was 104 cfu/ml.11,12 Only one isolate of the
same species per patient was included in the study. All microorgan-
isms isolated were identiﬁed by standard laboratory methods.
2.3. Statistical methods
Group patient characteristics were summarized using mean
(standard deviation), median (range), and number (%), as neces-
sary. Numerical data were ﬁrst tested for normality and then
analyzed using the Student’s t-test for parametric data; the Mann–
Whitney U-test was used for variables with non-parametric data
for group comparisons. Categorical data were analyzed using the
Chi-square test or Fisher’s exact test. Tests were two-tailed, and p-
values of 0.05 were considered signiﬁcant. Univariate analysis
was used to identify the risk factors for mortality of SCAP cases,
both in-hospital and in-ICU. To evaluate the independent risk
factors for in-hospital and in-ICU mortality, multivariate logistic
regression analysis was performed, incorporating all factors that
obtained p-values of <0.05 in the univariate analyses. Results of
the analysis are presented as p-values, odds ratios (OR), and 95%
conﬁdence intervals (CI). Statistical signiﬁcance was set at p < 0.05.
All analyses were done using SPSS for Windows version 18.0 (SPSS
Inc., Chicago, IL, USA).
3. Results
A total of 445 patients with SCAP were admitted to the 19 ICUs
during the study period. We excluded 32 patients found to be
ineligible for the study, hence a ﬁnal 413 patients were included in
Table 1
Univariate analysis for in-ICU mortality among the cases with severe CAP (N = 413)
Variable Non-survivors
(n = 117)
Survivors
(n = 296)
OR (95% CI) p-Value
Age, years, median (range) 69 (16–95) 66 (16–91) 0.039
Male sex, n (%) 72 (61.5) 209 (70.6) 0.667 (0.425–1.043) 0.075
Predisposing factors, n (%)
Cigarette smoking, n (%) 78 (66.7) 201 (67.9) 0.945 (0.600–1.490) 0.809
Alcohol consumption, n (%) 80 (68.4) 213 (71.9) 0.829 (0.520–1.320) 0.428
COPD, n (%) 50 (42.7) 159 (73.6) 0.643 (0.418–0.990) 0.044
Antibiotic use in last 3 months, n/N (%) (N = 239) 5/73 (6.8) 17/166 (10.2) 0.645 (0.228–1.819) 0.403
Systemic steroid use in last 3 months, n/N (%) (N = 339) 15/99 (15.2) 26/240 (10.8) 1.470 (0.742–2.913) 0.268
NIV treatment, n (%) 40 (34.2) 201 (67.9) 0.246 (0.156–0.386) <0.0001
Intubation with IMV, n (%) 84 (71.8) 88 (29.7) 6.017 (3.747–9.661) <0.0001
Time of IMV, days, median (range) 8 (0–48) 4 (0–39) 0.003
Comorbidities, n (%)
Diabetes mellitus 24 (20.5) 35 (11.8) 1.924 (1.087–3.406) 0.023
Hypertension 15 (19.2) 63 (80.8) 0.544 (0.296–1.00) 0.048
Coronary artery disease 3 (2.6) 28 (9.5) 0.252 (0.075–0.845) 0.017
Chronic hepatic failure 23 (19.7) 66 (22.3) 0.853 (0.501–1.451) 0.557
Alzheimer’s disease 5 (4.3) 5 (1.7) 2.598 (0.738–9.147) 0.155
Chronic renal failure 4 (3.4) 16 (5.4) 0.619 (0.203–1.893) 0.397
Pulmonary involvement, n (%)
Bilateral pulmonary involvement 53 (45.3) 100 (33.8) 1.616 (1.041–2.507) 0.032
Multilobar pulmonary involvement 76 (30.5) 173 (69.5) 1.318 (0.845–2.056) 0.223
PaO2/FiO2 250 93 (79.5) 222 (75.0) 1.292 (0.768–2.173) 0.334
Severity of disease, n (%)
Median PSI score (range) 151 (40–254) 125 (25–245) 0.001
Median CURB-65 score (range) 3 (0–5) 2 (0–5) 0.001
Median CAP PIRO score (range) 4 (1–8) 3 (0–7) 0.001
Presence of septic shock 50 (42.7) 31 (10.5) 6.617 (3.91–11.2) <0.0001
Treatment data, n (%)
Antibiotic treatment in accordance with guidelinesa 0.136
Inadequate 52 (44.4) 133 (44.9)
Rational 35 (29.9) 114 (38.5)
Inadequate, P. aeruginosa risk (+) 6 (5.1) 8 (2.7)
Over-treatment, P. aeruginosa risk () 24 (20.6) 41 (13.9)
Systemic steroid treatment, n (%) 35 (29.9) 65 (21.9) 1.517 (0.937–2.456) 0.089
Length of ICU stay, days, median (range) 9 (1–48) 7 (1–44) 0.120
ICU, intensive care unit; CAP, community-acquired pneumonia; OR, odds ratio; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; NIV, non-invasive
ventilation; IMV, intermittent mandatory ventilation; PSI, pneumonia severity index; PIRO, predisposition, insult, response, and organ dysfunction.
a Turkish CAP guideline.
Table 3
Microorganisms isolated from clinical culture specimens of severe CAP
Blood BAL NBL Total
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years; 281 (68%) were males and 132 (32%) were females.
The overall in-hospital mortality was 31.2% (129 patients) and
in-ICU mortality was 28.3% (117 patients). Thus, 12 patients died
after they were discharged from the ICUs. Three patients died of
terminal lung cancer after discharge, four patients, one of whom
had cystic ﬁbrosis, experienced cardiac arrest, one died due to a
cerebrovascular accident, two cases died of probable pulmonary
embolism, and the reason of death was undetermined in two cases.
The reasons for death were recorded for 47 patients (27.8%) in the
hospital records of some of our participating centers; these centers
provided 169 CAP patients hospitalized in the ICUs. For three of
them (1.8%), mortality was related to reasons other than CAP. Thus,
in this subgroup of patients, the attributable mortality related to
CAP in the ICU was 26%. A comparison between survivors and non-
survivors in the ICUs (survivors n = 296, non-survivors n = 117) is
shown in Table 1. The median age, intermittent mandatoryTable 2
Multivariate logistic regression analysis for in-ICU mortality among the cases with
severe CAP
OR 95% CI p-Value
Hypertension 0.297 0.094–0.943 0.039
Bilateral pulmonary involvement 2.461 1.062–5.704 0.036
CAP PIRO score 1.955 1.330–2.875 0.001
Non-invasive ventilation 0.192 0.079–0.466 0.001
ICU, intensive care unit; CAP, community-acquired pneumonia; OR, odds ratio; CI,
conﬁdence interval; PIRO, predisposition, insult, response, and organ dysfunction.ventilation (IMV), duration of IMV, diabetes mellitus, bilateral
pulmonary involvement on chest roentgenograms, median PSI
score, median CURB-65 score, median CAP PIRO score, and the
presence of septic shock on admission were signiﬁcantly different
between the two groups. There were no signiﬁcant differences
between the two groups regarding sex, cigarette smoking, alcohol
consumption, antibiotics and steroid use in the last 3 months,
chronic hepatic failure, Alzheimer’s disease, chronic renal failure,
the existence of multilobar pulmonary involvement on chest
roentgenogram, arterial gas analysis (PaO2/FiO2 250) on
admission, antibiotic treatment in accordance with the TurkishEnteric Gram-negatives 12
Klebsiella spp 2 2 1 5
Escherichia coli 1 2 1 4
Enterobacter cloacae 1 2 0 3
Staphylococcus aureus 5 5 0 10
Streptococcus pneumoniae 5 1 0 6
Pseudomonas aeruginosa 4 2 0 6
Acinetobacter spp 0 1 2 3
Moraxella catarrhalis 1 0 0 1
Stenotrophomonas maltophilia 0 1 0 1
% of recoverya 19/246 (7.7%) 16/78 (20.5%) 4/16 (25%)
CAP, community-acquired pneumonia; BAL, bronchoalveolar lavage; NBL, non-
bronchoscopic lavage.
a No. of isolated microorganisms/No. of samples obtained.
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of hospital stay in the ICU (Table 1).
Multivariate logistic regression analysis revealed that bilateral
pulmonary involvement (OR 2.461, 95% CI 1.062–5.704) and CAP
PIRO score (OR 1.955, 95% CI 1.330–2.875) were independent risk
factors for a higher in-ICU mortality. Both arterial hypertension
and the presence of non-invasive ventilation (NIV) appeared to
decrease mortality inside the ICUs (Table 2).
In this study, no culture of any kind was obtained for 90 (22%)
patients during the entire course of the hospitalization. A sputum
culture was obtained for 295 (71%) cases. The Legionella urinary
antigen test (UAT) was positive in one out of 18 cases, while the
pneumococcal UAT was found to be negative in eight cases tested.
Microorganisms isolated from blood, BAL, and NBL specimens
obtained within 48 h of hospital admission are presented in
Table 3.
4. Discussion
The mortality rate of CAP in patients admitted to the ICU
remains high, even in immunocompetent patients, despite
antibiotics and adequate supportive care.13 Antibiotics alone do
not entirely eliminate mortality in CAP patients requiring intensive
care support. The overall mortality rate in our study was 31%.
However, attributable mortality is a more accurate indicator,14–16
and this was reported for a quarter of the cases in this study. These
mortality rates are in accordance with rates reported from some
studies,17–19 but are lower than those of other studies.1,20–25 The
outcomes of CAP patients in the ICU reported in the literature seem
to depend on the interactions between various factors such as
comorbidities, age, genetic predisposition, host defenses, microbial
virulence and toxins, bacterial load, presence of organ failure,
timing of ICU admission, high severity index scores, the need for
surgical drainage for empyema, adjuvant therapies, and the choice
of antibiotics.5,26,27 According to our multivariate analysis,
bilateral pulmonary involvement and increasing CAP-PIRO score
were found to be independently associated with a higher mortality
inside the ICUs.
The CAP PIRO (predisposition, insult, response, and organ
dysfunction) score is a severity index, which includes comorbid-
ities (chronic obstructive pulmonary disease (COPD) and immu-
nocompromise), age >70 years, multilobar opacities on chest
radiograph, shock, severe hypoxemia, acute renal failure, bacter-
emia, and acute respiratory distress syndrome. The PIRO score for
the assessment of SCAP patients is a relatively new concept.28 An
initial study reported that the mean PIRO score of CAP patients in
the ICUs was signiﬁcantly higher in non-survivors than in
survivors.29 According to our data, an increase in the PIRO score
by one digit is associated with a 1.9-fold increase in the in-ICU
mortality. Thus, since the PIRO score integrates key signs and
symptoms of clinical sepsis and of major CAP risk factors, it may
provide a better means of predicting SCAP. On the other hand,
bilateral pulmonary involvement is a recognized parameter, which
is known to worsen the prognosis in this group of patients.30,31
Arterial hypertension and NIV seem to be correlated with a
lower mortality in the ICUs. To the best of our knowledge, a
connection between arterial hypertension and fatality has not
been shown. Although further studies are necessary on this issue,
antihypertensive drugs such as angiotensin-converting enzyme
(ACE) inhibitors are known to have anti-inﬂammatory and
immunomodulatory effects. The use of ACE inhibitors was shown
to decrease mortality in pneumonia patients in a population-based
study from the UK.32 In addition, a meta-analysis reported that ACE
inhibitors are associated with lower risks of pneumonia develop-
ment and of pneumonia-related mortality.33 On the other hand, it
is known that CAP patients with chronic pulmonary diseases orcardiac comorbid diseases have a greater chance of survival if they
have a good response to NIV.34 However, the efﬁcacy of NIV in
reducing intubation and mortality rates in CAP is still controversial.
Several studies have reported the effectiveness of NIV in
pneumonia patients, particularly those with COPD.35 Almost half
of our patients had COPD; this rate is higher than the rates of most
previous SCAP studies.1,36–38 Therefore, the high rate of COPD
patients might partly explain the contribution of NIV to better
survival. It has been reported that NIV eliminates the risks of
endotracheal intubation and provides better clinical improvement
in select cases than IMV, which may cause serious complica-
tions.39,40
Streptococcus pneumoniae, Legionella spp, and Gram-negative
bacilli represent the most common causative organisms of SCAP in
the Western countries.1,41,42 However there may be variations in
the etiological agents in different geographical areas. For
instance, pulmonary tuberculosis and Burkholderia pseudomal-
lei have been reported as the most signiﬁcant causes of SCAP in
Singapore.23 In a retrospective study in South Africa, Feldman
et al. reported different microbial proﬁles in patients with SCAP
admitted to the ICU, with a very low incidence of Legionella
pneumophila, Pseudomonas aeruginosa, and Staphylococcus
aureus, but high levels of Klebsiella pneumoniae.25 A small
study from Turkey revealed S. pneumoniae and Mycobacterium
tuberculosis to be the most signiﬁcant microorganisms  in SCAP
cases.43 In the present study, the most common organisms
were enteric Gram-negatives, followed by S. aureus, pneumo-
cocci, and P. aeruginosa.
According to Turkish, European, and American guidelines,
blood and sputum cultures, Legionella and pneumococcal UATs,
and if the patients are intubated, endotracheal aspirate, and
possibly bronchoscopy or non-bronchoscopic BAL are recom-
mended for all CAP patients admitted to the ICU.10,44,45 Since we
excluded the sputum culture data and we did not include the
culture results of those patients transferred from the wards to the
ICUs, due to the fact that cultures would have been obtained more
than 48 h after hospital admission in this circumstance, our
microbiological data are limited. Our aim was to disclose the true
community-acquired isolates and to exclude colonizers. On the
other hand, no culture of any kind was obtained for a ﬁfth of our
CAP patients in the ICUs, and both pneumococcal and Legionella
UATs were performed in a small portion of the cases. Thus, the
compliance of the clinicians to microbiological diagnostic
techniques appears to be low. Blood cultures disclosed the
pathogen in a tenth of cases, BAL in a ﬁfth, and NBL recovered the
infecting agent in a quarter of the cases. Thus, the importance of
the use of diagnostic microbiological tests should be underlined
for this fatal disease, along with the establishment of urgent
postgraduate training programs.
There are some limitations to our study. First, it was
designed retrospectively, and second, this study was conducted
mainly in respiratory ICUs. Therefore, the patient character-
istics of this study should be interpreted in that context. Third,
we were able to provide the actual cause of death in order to
estimate the attributable mortality for only a subgroup of
patients. We have now modiﬁed our database and in the future
we will be able to report the exact attributable mortality rate of
CAP patients in the ICUs. This study also has an important
strength when compared to the other studies in the literature:
a large number of cases were enrolled from 19 hospitals
located in various parts of Turkey.
In conclusion, CAP requiring ICU admission is associated with
considerable mortality. The treating clinician should be informed
of the importance of laboratory data and the prognostic factors
related to CAP patients admitted to the ICU.
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